Please assess the completion status of the following clinical trial:

Trial Title: STOP Persistent AF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of symptomatic persistent AF: Defined as having a continuous episode lasting longer than 7 days but less than 6 months documented by consecutive ECG recordings OR Defined as having a continuous episode lasting longer than 7 days but less than 6 months documented by an ECG recording and one doctor note indicating patient had symptoms consistent with AF~* Failure or intolerance of at least one Class I or III antiarrhythmic drug~* Age 18 or older (or older than 18 if required by local law)~Exclusion Criteria:~* Left atrial diameter \> 5.0 cm (anteroposterior)~* Prior left atrial ablation or surgical procedure (including left atrial appendage closures)~* Presence or likely implant of a permanent pacemaker, biventricular pacemaker, loop recorder, or any type of implantable cardiac defibrillator (with or without biventricular pacing function) within 12 months~* Presence of any pulmonary vein stents~* Presence of any pre-existing pulmonary vein stenosis~* Pre-existing hemidiaphragmatic paralysis~* Presence of any cardiac valve prosthesis~* +3 and +4 mitral valve regurgitation or stenosis~* Any cardiac surgery, myocardial infarction, percutaneous coronary intervention (PCI) / percutaneous transluminal coronary angioplasty (PTCA) or coronary artery stenting which occurred during the 3 month interval preceding the consent date~* Unstable angina~* New York Heart Association (NYHA) Class III or IV congestive heart failure and/or documented left ventricular ejection fraction (LVEF) less than or equal to 35% measure by acceptable cardiac testing (e.g. Transthoracic echocardiogram (TTE))~* Primary pulmonary hypertension~* Rheumatic heart disease~* Thrombocytosis, thrombocytopenia~* Any condition contraindicating chronic anticoagulation~* Active systemic infection~* Hypertrophic cardiomyopathy~* Cryoglobulinemia~* Uncontrolled hyperthyroidism~* Any cerebral ischemic event (strokes or transient ischemic attacks (TIAs)) which occurred during the 6 month interval preceding the consent date~* Any woman known to be pregnant or breastfeeding, or any woman of child bearing potential who is not on a reliable form of birth regulation method or abstinence~* Life expectancy less than one year~* Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre-approved by Medtronic~* Known allergies or hypersensitivities to adhesives~* Known drug or alcohol dependency~* Unwilling or unable to comply fully with study procedures and follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete